1. Home
  2. XLO vs RDI Comparison

XLO vs RDI Comparison

Compare XLO & RDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

XLO

Xilio Therapeutics Inc.

N/A

Current Price

$9.04

Market Cap

56.9M

Sector

Health Care

ML Signal

N/A

Logo Reading International Inc

RDI

Reading International Inc

HOLD

Current Price

$2.01

Market Cap

49.0M

ML Signal

HOLD

Company Overview

Basic Information
Metric
XLO
RDI
Founded
2016
1937
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Movies/Entertainment
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
56.9M
49.0M
IPO Year
2021
1994

Fundamental Metrics

Financial Performance
Metric
XLO
RDI
Price
$9.04
$2.01
Analyst Decision
Buy
Analyst Count
1
0
Target Price
★ $28.00
N/A
AVG Volume (30 Days)
9.2K
★ 85.0K
Earning Date
05-14-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 60.76
EPS
N/A
★ N/A
Revenue
$43,766,000.00
★ $202,988,000.00
Revenue This Year
N/A
$16.25
Revenue Next Year
$168.77
$4.04
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 589.88
N/A
52 Week Low
$0.46
$0.94
52 Week High
$9.90
$2.41

Technical Indicators

Market Signals
Indicator
XLO
RDI
Relative Strength Index (RSI) 48.64 50.19
Support Level $8.63 $0.99
Resistance Level $9.15 $2.41
Average True Range (ATR) 0.24 0.13
MACD 0.00 -0.04
Stochastic Oscillator 21.83 14.70

Price Performance

Historical Comparison
XLO
RDI

About XLO Xilio Therapeutics Inc.

Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.

About RDI Reading International Inc

Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.

Share on Social Networks: